Literature DB >> 33974173

Structure-Based SAR in the Design of Selective or Bifunctional Nociceptin (NOP) Receptor Agonists.

Michael E Meyer1, Arpit Doshi1, Dennis Yasuda1, Nurulain T Zaveri2.   

Abstract

The nociceptin opioid receptor (NOP), the fourth member of the opioid receptor family, and its endogenous peptide ligand, nociceptin or orphanin FQ (N/OFQ), play a vital role in several central nervous system pathways regulating pain, reward, feeding, anxiety, motor control and learning/memory. Both selective NOP agonists as well as bifunctional agonists at the NOP and mu opioid receptor (MOP) have potential therapeutic applications in CNS disorders related to these processes. Using Surflex-Dock protocols, we conducted a computational structure-activity study of four scaffold classes of NOP ligands with varying NOP-MOP selectivity. By docking these compounds into the orthosteric binding sites within an active-state NOP homology model, and an active-state MOP crystal structure, the goal of this study was to use a structure-based drug design approach to modulate NOP affinity and NOP vs. MOP selectivity. We first docked four parent compounds (no side chain) to determine their binding interactions within the NOP and MOP binding pockets. Various polar sidechains were added to the heterocyclic A-pharmacophore to modulate NOP ligand affinity. The substitutions mainly contained a 1-2 carbon chain with a polar substituent such as an amine, alcohol, sulfamide, or guanidine. The SAR analysis is focused on the impact of structural changes in the sidechain, such as chain length, hydrogen bonding capability, and basic vs neutral functional groups on binding affinity and selectivity at both NOP and MOP receptors. This study highlights structural modifications that can be leveraged to rationally design both selective NOP and bifunctional NOP-MOP agonists with different ratios of functional efficacy.

Entities:  

Keywords:  active-state; homology model; nociceptin receptor; pharmacophore; selective or bifunctional nociceptin agonist; structure-based drug design

Year:  2021        PMID: 33974173     DOI: 10.1208/s12248-021-00589-7

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  39 in total

1.  Identification of the G-protein-coupled ORL1 receptor in the mouse spinal cord by [35S]-GTPgammaS binding and immunohistochemistry.

Authors:  M Narita; H Mizoguchi; D E Oji; N J Dun; B H Hwang; H Nagase; L F Tseng
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

2.  Nociceptin/orphanin FQ microinjected into hippocampus impairs spatial learning in rats.

Authors:  J Sandin; J Georgieva; P A Schött; S O Ogren; L Terenius
Journal:  Eur J Neurosci       Date:  1997-01       Impact factor: 3.386

3.  cDNA cloning and regional distribution of a novel member of the opioid receptor family.

Authors:  K Fukuda; S Kato; K Mori; M Nishi; H Takeshima; N Iwabe; T Miyata; T Houtani; T Sugimoto
Journal:  FEBS Lett       Date:  1994-04-18       Impact factor: 4.124

4.  Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type.

Authors:  J R Bunzow; C Saez; M Mortrud; C Bouvier; J T Williams; M Low; D K Grandy
Journal:  FEBS Lett       Date:  1994-06-27       Impact factor: 4.124

5.  Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress.

Authors:  F Jenck; J L Moreau; J R Martin; G J Kilpatrick; R K Reinscheid; F J Monsma; H P Nothacker; O Civelli
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

Review 6.  Nociceptin/orphanin FQ-NOP receptor system in inflammatory and immune-mediated diseases.

Authors:  Elaine C Gavioli; Iris Ucella de Medeiros; Marta C Monteiro; Girolamo Calo; Pedro R T Romão
Journal:  Vitam Horm       Date:  2015-01-14       Impact factor: 3.421

7.  Molecular cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family.

Authors:  Y Chen; Y Fan; J Liu; A Mestek; M Tian; C A Kozak; L Yu
Journal:  FEBS Lett       Date:  1994-06-27       Impact factor: 4.124

8.  ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization.

Authors:  C Mollereau; M Parmentier; P Mailleux; J L Butour; C Moisand; P Chalon; D Caput; G Vassart; J C Meunier
Journal:  FEBS Lett       Date:  1994-03-14       Impact factor: 4.124

9.  Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor.

Authors:  J C Meunier; C Mollereau; L Toll; C Suaudeau; C Moisand; P Alvinerie; J L Butour; J C Guillemot; P Ferrara; B Monsarrat
Journal:  Nature       Date:  1995-10-12       Impact factor: 49.962

10.  Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor.

Authors:  R K Reinscheid; H P Nothacker; A Bourson; A Ardati; R A Henningsen; J R Bunzow; D K Grandy; H Langen; F J Monsma; O Civelli
Journal:  Science       Date:  1995-11-03       Impact factor: 47.728

View more
  1 in total

1.  Attenuated G protein signaling and minimal receptor phosphorylation as a biochemical signature of low side-effect opioid analgesics.

Authors:  Pooja Dasgupta; Anika Mann; Willma E Polgar; Rainer K Reinscheid; Nurulain T Zaveri; Stefan Schulz
Journal:  Sci Rep       Date:  2022-05-03       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.